All In Biotech

Drug Trial Radar · NCT02274558

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia

Last checked: Nov 20, 2026Latest source record: Jul 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 234 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

234

Actual

Start

Oct 2014

Primary completion

Sep 2015

Study completion Jul 2016

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Oct 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.

Conditions

  • Tardive Dyskinesia

Interventions

  • NBI-98854Drug

    NBI-98854 40 mg capsules

  • PlaceboDrug

    NBI-98854 placebo capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6Time frame: Baseline and Week 6

Locations

54 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Glendale, California

  • Site not named

    Irvine, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    National City, California

  • Site not named

    Norwalk, California

  • Site not named

    Oakland, California

  • Site not named

    Oceanside, California

  • Site not named

    San Bernardino, California

  • Site not named

    San Diego, California

  • Site not named

    Torrance, California

  • Site not named

    Bradenton, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Kissimmee, Florida

  • Site not named

    Leesburg, Florida

  • Site not named

    Maitland, Florida

  • Site not named

    Miami, Florida

  • Site not named

    North Miami, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Oak Brook, Illinois

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Glen Burnie, Maryland

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Flowood, Mississippi

  • Site not named

    St Louis, Missouri

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Amherst, New York

  • Site not named

    Cedarhurst, New York

  • Site not named

    Rochester, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Pinehurst, North Carolina

  • Site not named

    Dayton, Ohio

  • Site not named

    Shaker Heights, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Conshohocken, Pennsylvania

  • Site not named

    Norristown, Pennsylvania

  • Site not named

    Phoenixville, Pennsylvania

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.